BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (NASDAQ: OCUL) investors concerning the Company and its officers’ possible violations of federal securities laws.
On May 5, 2017, the Company disclosed that it received a Form 483 from the FDA containing “inspectional observations” related to the Company’s manufacturing and analytical testing procedures.
Then, on July 6, 2017, a report was published on SeekingAlpha.com alleging that management had been misleading investors regarding the severity of the Company’s manufacturing troubles. On this news, the Company’s share price fell more than 22% during intraday trading on July 7, 2017, thereby injuring investors.
If you purchased Ocular securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to email@example.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.